Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32,146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison.
Mateos MV, San-Miguel J, Goldschmidt H, Sonneveld P, Dimopoulos MA, Heeg B, Hashim M, Deraedt W, Hu P, Lam A, He J. Mateos MV, et al. Among authors: he j. Leuk Lymphoma. 2020 Mar;61(3):680-690. doi: 10.1080/10428194.2019.1675881. Epub 2019 Nov 5. Leuk Lymphoma. 2020. PMID: 31686561
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho KF, Van Rampelbergh R, Uhlar CM, Wang J, Kobos R, Gries KS, Fastenau J, Weisel K. Perrot A, et al. Among authors: he j. J Clin Oncol. 2021 Jan 20;39(3):227-237. doi: 10.1200/JCO.20.01370. Epub 2020 Dec 16. J Clin Oncol. 2021. PMID: 33326255 Free PMC article. Clinical Trial.
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Facon T, San-Miguel J, Dimopoulos MA, Mateos MV, Cavo M, van Beekhuizen S, Yuan Z, Mendes J, Lam A, He J, Ammann E, Kumar S. Facon T, et al. Among authors: he j. Adv Ther. 2022 Aug;39(8):3868-3869. doi: 10.1007/s12325-022-02211-4. Adv Ther. 2022. PMID: 35764866 Free PMC article. No abstract available.
Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible.
Sonneveld P, Mateos MV, Alegre A, Facon T, Hulin C, Hashim M, Vincken T, Kampfenkel T, Cote S, He J, Lam A, Moreau P. Sonneveld P, et al. Among authors: he j. EJHaem. 2020 Aug 25;1(2):481-488. doi: 10.1002/jha2.77. eCollection 2020 Nov. EJHaem. 2020. PMID: 35845005 Free PMC article.
Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matching.
Moreau P, Hulin C, Zweegman S, Hashim M, Hu Y, Heeg B, de Boer C, Vanquickelberghe V, Kampfenkel T, He J, Lam A, Cote S, Sonneveld P. Moreau P, et al. Among authors: he j. EJHaem. 2020 Nov 7;2(1):66-80. doi: 10.1002/jha2.129. eCollection 2021 Feb. EJHaem. 2020. PMID: 35846097 Free PMC article.
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.
Moreau P, Hebraud B, Facon T, Leleu X, Hulin C, Hashim M, Hu Y, Caillot D, Benboubker L, Zweegman S, Merz M, Weisel K, Salwender H, Mai EK, Goldschmidt H, Bertsch U, Vanquickelberghe V, Kampfenkel T, Boer C, Krotneva S, Proskorovsky I, He J, Lam A, Lee C, Cote S, Sonneveld P. Moreau P, et al. Among authors: he j. Immunotherapy. 2021 Feb;13(2):143-154. doi: 10.2217/imt-2020-0266. Epub 2020 Nov 24. Immunotherapy. 2021. PMID: 33228440
32,146 results
You have reached the last available page of results. Please see the User Guide for more information.